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ABSTRACT: Deposition of amorphous aggregates and fibrils
of transthyretin (TTR) in leptomeninges and subarachnoid
vessels is a characteristic of leptomeningeal amyloidosis (LA),
a currently untreatable cerebral angiopathy. Herein, we report
the X-ray structure of the A25T homotetramer of TTR, a
natural mutant described in a patient with LA. The structure of
A25T-TTR is indistinguishable from that of wild-type TTR
(wt-TTR), indicating that the difference in amyloidogenicity
between A25T-TTR and wt-TTR cannot be ascribed to gross
structural differences. Using pressure-induced dissociation of
the tetramer, we show that A25T-TTR is 3 kcal/mol less stable
than L55P-TTR, the most aggressive mutant of TTR described to date. After incubation for 15 days at 37 °C (pH 7.3), A25T-
TTR forms mature amyloid fibrils. To mimic the environment in which TTR aggregates, we investigated aggregation in
cerebrospinal fluid (CSF). Unlike L55P-TTR, A25T-TTR rapidly forms amyloid aggregates in CSF that incorporated several
protein partners. Utilizing a proteomics methodology, we identified 19 proteins that copurified with A25T-TTR amyloid fibrils.
We confirmed the presence of proteins previously identified to be associated with TTR aggregates in biopsies of TTR
amyloidosis patients, such as clusterin, apolipoprotein E, and complement proteins. Moreover, we identified novel proteins, such
as blood coagulation proteins. Overall, our results revealed the in vitro characterization of TTR aggregation in a biologically
relevant environment, opening new avenues of investigation into the molecular mechanisms of LA.
Protein misfolding diseases include a broad range ofpathologies in which proteins fail to fold properly and
are degraded or cease to remain in their folded state once
folded, populating partially denatured states.1 At sufficient
concentrations, partially denatured states can lead to protein
aggregation, resulting in a spectrum of quaternary structures,
including oligomers, protofibrils, and fibrils.2 Many degener-
ative diseases are associated with protein cross-β-sheet
quaternary structure, or amyloid fibril, formation termed the
amyloidoses.3 Amyloid deposits can be detected using Congo
red birefringence or thioflavin T fluorescence and are often
associated with glycosaminoglycans, the amyloid P component,
and other proteins. Amyloid filaments often share an in-register
parallel cross-β quaternary structure in which the strands are
oriented perpendicular to the fibril axis. Amyloid fibrils usually
consist of multiple interacting filaments that are at least two β-
sheets thick.4−6 Some fibrils are formed by a highly ordered
triangular core, which is in turn formed by three parallel cross-β
sheets.7 On the basis of the generic nature of these assemblies,
it has been proposed that any protein, regardless of its amino
acid sequence, can form amyloid fibrils if subjected to
appropriate solution conditions.8,9
Transthyretin (TTR) is a 54 kDa homotetrameric protein
composed of identical 127-residue subunits exhibiting a
predominantly β-sheet tertiary structure.10 TTR is secreted
into the human bloodstream by the liver and into the
cerebrospinal fluid (CSF) by the choroid plexus. Each TTR
monomer is composed of one α-helix and eight β-strands
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(denoted A−H) arranged in a characteristic sandwich of two β-
sheets [DAGH and CBEF (Figure 1)]. The dimer (AB) is held
together by antiparallel β-sheet hydrogen bonds and hydro-
phobic side chain−side chain interactions involving the H
strands located along the edge of each monomer. Two dimers
(AB and CD) associate back to back via hydrophobic
interactions involving residues of the loops that connect
strands AB and GH, creating the less stable dimer−dimer
interface.11
In the blood, TTR serves as a tertiary carrier for thyroxine
(T4), and as such, 99% of its binding sites are unoccupied.
TTR binds to and carries ∼0.5 equiv of retinol-binding protein
in the blood.12 In the CSF, TTR is the primary T4
transporter.13 Secreted TTR can form amyloid fibrils in the
extracellular space, leading to various amyloid-related pathol-
ogies. The amyloidogenesis of wild-type TTR (wt-TTR) leads
to senile systemic amyloidosis, a cardiomyopathy that affects
10−25% of people more than 70 years of age and is
characterized by heavy amyloid deposits in the heart.14 The
amyloidogenesis of more than 80 point mutations of TTR
appears to cause familial amyloidotic polyneuropathy (FAP)
and/or familial amyloidotic cardiomyopathy (FAC), or central
nervous system amyloidosis (CNSA).15 Among the variants of
TTR, the V30M and V122I (3% of people of African descent
have this mutation) TTR mutations are the clinically most
important because of their high frequency of occurrence in
causing FAP and FAC, respectively. On the other hand, A25T
is one of rare TTR mutations associated with an amyloidosis
that is restricted to the central nervous system (CNS) and is
characterized by the deposition of amyloid fibrils in the
leptomeningeal and subarachnoid vessels.16 Sekijima and co-
workers16 have described tetramers composed of this mutant
subunit as being highly unstable. Although tetramer instability
is positively correlated with pathology severity and onset,17−20
A25T-related amyloidosis has a late onset and is peculiar in that
it does not result in a peripheral amyloid disease, only a brain
disease. Because of the instability of the A25T-TTR tetramer,
this protein is detected as being misfolded in the endoplasmic
reticulum of liver cells and is largely degraded by the
proteasome instead of being secreted into the bloodstream.
The high concentration of T4 in the choroid plexus serves as a
pharmacologic chaperone enhancing TTR tetramer folding
efficiency in the endoplasmic reticulum, leading to secretion of
the A25T subunit-containing TTR tetramer.20 After secretion,
the T4 no longer binds, allowing dissociation of the tetramer
and subsequent A25T TTR amyloidogenesis.
Several hypotheses have been proposed to explain the
amyloidogenic properties of TTR. The hypothesis consistent
with all the data posits the dissociation of the tetramer into a
monomeric, partially unfolded state, which aggregates by a
Figure 1. Ribbon diagram of transthyretin (TTR). (A) Schematic representation of the secondary structure of TTR generated using PDBsum, where
β-strands A−H are represented by arrows and the α-helix is represented by a cylinder. C and N represent the C- and N-termini of the protein,
respectively. (B) Schematic representation of the TTR dimer composed of monomers A and B with the two β-sheets (DAGH and CBEF)
represented in each monomer.
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thermodynamically favorable misassembly process (nucleation
not required).2,21−25 Investigations have shown that disruption
of β-strands C and D may expose hydrophobic regions of the
protein to solvent, leading to aggregation.26−28 Recently, we
have shown that TTR has three canonical Zn2+-binding sites.29
Zn2+ binding induces structural perturbations that lead to TTR
aggregation.29,30 Most studies have used acidic pH to induce
TTR aggregation16,18 in vitro. However, it is still unknown
whether TTR is exposed to acidic environments during its
lifetime23 or how the tetramer dissociation and partial
monomer unfolding required for amyloidogenesis occur in
vivo. Thus, ex vivo studies mimicking in vivo conditions are
required for an improved understanding of the mechanisms
behind TTR aggregation to define possible targets for effective
therapies against TTR-related amyloidosis.31
Currently, FAP patients are treated by liver transplant, in
which a patient’s liver expressing a TTR variant, typically
V30M, is replaced by one that expresses the wt protein.
Although liver transplantation retards the progression of FAP, it
does not eliminate aggregates that have already been
deposited.32 Moreover, many FAP patients later develop
cardiomyopathy from deposition of wt-TTR on top of prior
deposition of V30M. There is, however, no treatment for
patients bearing CNSA-related TTR mutations, and surpris-
ingly, liver transplantation does not seem to be effective for all
disease-associated variants.33−35
Many studies have focused on developing effective and
selective TTR ligands that can prevent TTR dissociation and
aggregation.36−39 Nonsteroidal anti-inflammatory drugs
(NSAIDs) have been described as effective stabilizers of TTR
tetramers,40 and most recently, the Committee for Medicinal
Products for Human Use recommended the granting of a
marketing authorization for the drug Vyndaqel (tafamidis) for
the treatment of FAP patients (http://www.ema.europa.eu).
In this study, we investigated one of the variants whose
amyloidogenesis leads to CNSA, A25T-TTR. The X-ray
structure of the A25T-TTR homotetramer was determined to
2.03 Å resolution. In keeping with all of the amyloid disease-
associated TTR mutants studied to date, the structure of A25T-
TTR showed no profound alterations relative to the wt-TTR
structure. Through the use of high hydrostatic pressure, we
were able to assess the thermodynamic parameters (ΔGa and
ΔVa) of A25T-TTR folding and association, and we showed
that A25T-TTR is less stable than one of the most destabilized
variants, L55P-TTR, that leads to very early onset polyneur-
opathy. Utilizing an array of techniques, we analyzed the A25T-
TTR aggregation kinetics in buffer at pH 7.3, as well as in CSF,
the environment in which it aggregates in vivo. Interestingly,
the amyloid fibrils formed in CSF were composed of several
other proteins besides TTR that are present in this complex
physiological environment.
■ EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant TTR. The
expression and purification of recombinant wt-TTR and the
A25T-TTR and L55P-TTR mutants were performed as
previously described.41 For the A25T-TTR variant, the 30
min incubation at 60 °C41 was omitted because of the
instability of this protein. The protein concentration was
measured and calculated using an extinction coefficient of 7.76
× 104 M−1 cm−1 at 280 nm.
Spectroscopic Measurements under High Hydrostatic
Pressure (HHP). HHP has been described elsewhere as an
effective tool for the study of protein folding and oligomeriza-
tion.42 We used a high-pressure cell equipped with optical
windows43 (ISS Inc., Champaign, IL). Fluorescence spectra
were recorded on an ISS K2 spectrofluorimeter (ISS Inc.). In
all experiments, protein was diluted in buffer containing 25 mM
Tris-HCl, 50 mM KCl, and 1 mM EDTA (pH 7.5), and the
pressure was increased in steps of 200 bar. At each step, the
sample was allowed to equilibrate for 20 min prior to
measurements, and protein denaturation was monitored using
the tryptophan emission spectra. The mean energy of the
fluorescence emission was evaluated by calculating the center of
spectral mass ⟨vp⟩ at pressure p:
(1)
where Fi is the fluorescence emitted at wavelength vi. The
degree of dissociation (α) is related to ⟨vp⟩ by the expression
(2)
where ⟨νi⟩ and ⟨νf⟩ are the initial and final values of the center
of spectral mass, respectively, in nanometers.
We noted that the initial center of spectral mass values for all
proteins used in HHP assays were recovered after decom-
pression.
Thermodynamic Parameters. The standard volume
changes upon folding (ΔVa) for the A25T-TTR and L55P-
TTR mutants and the equilibrium dissociation constants (Kd)
were determined using the thermodynamic relation
(3)
This equation permits the calculation of the standard volume
change, ΔVa, for a tetramer ↔ monomer equilibrium from
measurements at a fixed protein concentration C at different
pressures. A change in protein concentration from C1 to C2 at a
fixed pressure results in a parallel displacement (Δp) of the plot
of ln[αp
4/(1 − αp)] versus p. At 50% dissociation, this shift
(Δp1/2) in pressure with the change in concentration is given
by eq 4, which allows the determination of the half-maximal
pressure capable of dissociating each protein concentration
under a given condition:17
(4)
Crystallization, Data Collection, and Structure Refine-
ment of A25T-TTR. A25T-TTR was crystallized by hanging-
drop vapor diffusion. Crystals were grown for 1 week at 20 °C
in buffer containing 100 mM HEPES, 200 mM CaCl2, and 28%
PEG400 (pH 7.5) via equilibration of 1 μL of 10 mg/mL TTR
with 1 μL of buffer solution. The A25T-TTR X-ray diffraction
data were collected using a home source (Rigaku Micromax
007HF with Varimax HF mirrors and an RAXIS IV++ IP
detector employing Cu Kα radiation; λ = 1.5418 Å) (Table 1).
The data were collected at 100 K using 1° oscillations per
image for a total of 100 images. The diffraction data were
processed using XDS44 up to 2.05 Å resolution. The structure
of A25T-TTR was determined by molecular replacement with
Phaser45 using the apo form of human TTR as a search model
(Protein Data Bank entry 3CFM). The refinement was
performed using Phenix46 and Coot.47 The electron density
for the A25T-TTR mutation was clearly identifiable, allowing
the correct positioning of the T25 side chain. Validation of the
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structural model was performed with Procheck48 and
Molprobity.49
Size-Exclusion Chromatography. The formation of
aggregates was monitored by size-exclusion chromatography
on a GPC 300 column (SynChropak) coupled to a high-
performance liquid chromatography system (Shimadzu SPD-
10A). The system was equilibrated in buffer containing 25 mM
Tris-HCl, 50 mM KCl, and 1 mM EDTA (pH 7.3) at a flow
rate of 0.4 mL/min. Protein samples were prepared in PBS and
aged at 37 °C for 20 days. Samples were withdrawn at different
times for size-exclusion gel filtration chromatography, and
sample elution was monitored by tryptophan fluorescence at
330 nm and absorbance at 280 nm. The peak areas for the
estimated tetramer elution volume and the aggregate elution
volume were calculated.
Congo Red and Thioflavin T Binding Assays. Fibril
formation was assessed using Congo red and thioflavin T (thio-
T) binding assays. Congo red binding was analyzed using
fluorescence microscopy in a Nikon TE 3000 microscope
(Zeiss). The samples were pelleted and resuspended in 5 mM
potassium phosphate and 150 mM NaCl (pH 7.4) containing
10 μM Congo red. A small amount was dropped onto a glass
slide and analyzed. For thio-T binding assays, fibril pellets were
diluted to 45 μg/mL in 5 mM potassium phosphate and 150
mM NaCl (pH 7.4) containing 20 μM thio-T, and binding was
monitored using a spectrofluorimeter to measure the
fluorescence increase (excitation at 450 nm and fluorescence
emission at 465−520 nm).
Western Blot and Dot-Blot Assays. Samples of wt-TTR
and the A25T-TTR and L55P-TTR variants, at a concentration
of 3.5 μM, were incubated for 11 days at 37 °C in phosphate
buffer (pH 7.3) (PBS). Aliquots were adsorbed on a PVDF
membrane that had been previously washed in methanol.
Membranes were blocked with 5% skim milk, washed with Tris-
buffered saline containing 0.05% Tween 20 (pH 7.5) (TTBS),
and incubated overnight at 4 °C with the A11 antibody
(1:5000)50 or a rabbit polyclonal anti-TTR antibody (1:10000)
(Dako, Carpinteria, CA). Membranes were then washed
thoroughly with TTBS and incubated with goat polyclonal
anti-rabbit IgG conjugated to horseradish peroxidase
(1:10000). Samples were visualized using an ECLplus kit
(GE Healthcare).
Aggregation of TTR in Human CSF. Aggregation was
performed via incubation of 3.5 μM A25T-TTR or L55P-TTR
in PBS or human CSF (Biochemed Services, Winchester, VA)
containing 5 mM NaN3 for 15 days at 37 °C. Samples were
taken daily, diluted 10-fold, and submitted to 12% native PAGE
at 4 °C and 100 V. The samples were transferred to PVDF
membranes, and Western blotting was performed as described
above. The bands were quantified using ImageJ. The fraction of
remaining tetramers was calculated from the native PAGE
analysis by dividing the area of the remaining tetramer by the
area of the tetramer on the first day of the kinetic analysis.
Electron Microscopy (EM). After aggregation for 15 days
in PBS or CSF, the samples were centrifuged at 16000g for 30
min at 4 °C to obtain insoluble fractions. These aggregates
were washed twice with PBS and resuspended in ddH2O,
yielding 45 μg/mL protein. Copper grids (carbon- and
Formvar-coated 400 mesh) (Electron Microscopy Sciences,
Hatfield, PA) were glow-discharged and inverted on a 5 μL
aliquot of sample for 3 min. Excess sample was removed, and
the grids were immediately placed briefly on a droplet of
doubly distilled water followed by a 2% uranyl acetate solution
for 2 min. Excess stain was removed and the grid allowed to dry
thoroughly. Grids were then examined on a Philips CM100
electron microscope (FEI, Hillsbrough, OR) at 80 kV and
images collected using a Megaview III ccd camera (Olympus
Soft Imaging Solutions, Lakewood, CO).
Analyses of Proteins that Co-Aggregate with A25T-
TTR Fibrils. A25T-TTR aggregates were obtained from A25T-
TTR (3.5 μM) aged for 15 days at 37 °C in PBS or human CSF
containing 5 mM NaN3. The samples were centrifuged at
16000g for 30 min at 4 °C to yield insoluble fractions. These
aggregates were washed twice with PBS and resuspended in
PBS, and the protein concentration was determined using
bicinchoninic acid reagent. As a control, we incubated human
CSF with 3.5 μM recombinant wt-TTR under the same
conditions. In this case, no aggregated material was observed.
The samples were separated by 4 to 12% SDS−PAGE and
stained with Coomassie blue G 250 or submitted to proteomics
analysis. For proteomics study, the samples were treated with
Rapigest (Waters), reduced with 200 mM DTT, alkylated with
200 mM iodoacetamide, and digested with trypsin overnight
using an estimated 1:30 enzyme:substrate ratio. One-dimen-
sional liquid chromatography and mass spectrometry (LC−
MS/MS) was performed on an Agilent q-TOF mass
spectrometer as described previously.51 The proteomic data
analysis was performed using the NCBInr database as described
previously.51 Two different CSF batches were assayed
independently by proteomics analysis, and only proteins
identified in both batches were considered positive hits. The
biological process classification was performed using UniProt
(http://www.uniprot.org).
Data Processing. For experiments shown in Figures 3A,B,
4D,F,G, and 5B,E, the error bars represent the SD of three
independent measurements. For experiments shown in Figure
Table 1. Full Data Collection and Refinement Statistics for
A25T-TTR
Data Collection
space group P21212
cell dimensions a, b, c (Å) 43.08, 64.17, 85.55
detector RAXIS IV++
X-ray source Rigaku MicroMax007 VarimaxHF
wavelength (Å) 1.5418
resolution range (Å) 20.0−2.03 (2.15−2.03)
redundancy 3.77 (3.5)
Rmeas (%) 11.4 (72.0)
completeness (%) 98.7 (94.6)
total no. of reflections 59145(8258)
no. of unique reflections 15676 (2494)
I/σ(I) 9.94 (2.22)
Refinement
no. of reflections used for refinement 15663
R (%) 19.12
Rfree (%) 23.94
overall averaged B factor (Å2) 35.70
no. of protein atoms 1797
no. of water molecules 167
Ramachandran plot
favored region (%) 99.5
outliers (%) 0.5
rmsd from ideal geometry
bond lengths (Å) 0.004
bond angles (deg) 0.668
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3C,D, the error bars represent the SD of two independent
measurements. The data in Figure 3B were statistically different
(p < 0.05; Student's t test).
For Table 3 and Table 1 of the Supporting Information, a
Mascot score of >4552 was taken as a significant threshold (p <
0.05). The Exponentially Modified Protein Abundance Index
(emPAI)53 offers a relative quantification of the proteins
present in the proteomic experiments (Table 3 and Table 1 of
the Supporting Information).
(5)
where Nobserved is the number of experimentally observed
peptides and Nobservable is the calculated number of observable
peptides for each protein.
■ RESULTS AND DISCUSSION
The Structure of Homotetrameric A25T-TTR Deter-
mined Crystallographically Reveals No Substantial
Structural Changes Relative to the wt-TTR Structure.
The structures of several amyloidogenic variants of TTR has
been determined crystallographically, but none of these offer a
clear indication of why these variants have increased
amyloidogenic potential compared to that of the wt protein.54
However, thermodynamic and kinetic studies have shown a
clear decrease in tetramer stability and, in some cases, an
increase in the rate of dissociation of the tetramer into
monomers, explaining why the familial TTR variants are more
amyloidogenic.16−20,25,55 The highly amyloidogenic A25T-TTR
variant exemplifies this correlation because its tetramer has the
highest dissociation rate constant of all of the TTR variants
studied thus far and is thermodynamically unstable.16 Because
the crystal structure of A25T-TTR has not yet been
determined, we decided to determine its structure using X-
ray crystallography to determine if, in contrast to the other
TTR variants, structural defects could explain the instability and
consequent amyloidogenicity of A25T-TTR.
Figure 2A shows that the overall structure of the A25T-TTR
homotetramer determined to 2.03 Å resolution remains largely
Figure 2. Comparison between the crystal structures of wt-TTR and A25T-TTR. (A) Superposition of wt-TTR (red) and A25T mutant (blue)
tetramers. The alanine of the wild-type structure is colored yellow and the threonine of A25T green. The overall rmsd for the 430 superposed Cα
atoms is 0.50 Å. (B) Image showing the local environment of the threonine mutation in monomer A. None of the possible rotamers for the
threonine side chain (green) leads to the formation of a hydrogen bond with the γ-hydroxyl group. (C) Standard omit map (Fobs − Fcalc contoured at
3σ) for the region surrounding the A25T mutation (residues 21−27) in monomer A.
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unaltered by the A25T mutation. The root-mean-square
deviation on superposition of the 460 equivalent Cα atoms
of the wild-type and mutant structures was only 0.50 Å. The
introduction of the threonine leads to only relatively minor
perturbations of the structure, which are restricted to the
vicinity of the mutation itself. The most notable difference with
respect to the wt-TTR structure is a local shift in the main
chain leading to a movement on the order of 0.9 Å of the Cα
atom at position 25. This appears necessary for accommodation
of the larger threonine side chain. The latter remains unsatisfied
in terms of its hydrogen bonding valencies as its local
environment provides no appropriate acceptor or donor for
the side chain hydroxyl group. Rather, the environment is
largely hydrophobic, composed of V16, V28, L111, and the
aromatic ring of Y78 (Figure 2B), appropriate for accommodat-
ing the alanine side chain of the wild-type protein. Indeed, the
electron density (Figure 2C) shows that the side chain of T25
exhibits some signs of disorder, presumably because none of the
potential rotamers leads to the formation of hydrogen bonds
that are expected when polar side chains are buried within the
protein core.56
A crystallographic 2-fold axis generates the full tetrameric
molecule from the two subunits [A and B (Figure 1B)] of the
asymmetric unit (Figure 2A). Clearly, therefore, the A25T
mutation is insufficient to perturb the stability of the native
quaternary structure of TTR under the conditions used for
crystallization. However, it is noteworthy that the A25T
mutation lies close to the dimer−dimer interface (Figure 2A).
Although the crystal structure itself provides no direct evidence
of this, it seems plausible that the local perturbations described
above, including the weakening of the side chain packing
induced by the electrostatically unsatisfied threonine side chain,
could lead to local instability of the monomeric or tetrameric
structure. In solution, this may propagate to the β-hairpin,
which precedes the mutation, and is part of the dimer−dimer
interface. This may eventually affect the overall stability of the
tetramer. Systematic urea denaturation studies conducted as a
function of TTR concentration showed that tetramer
dissociation and monomer unfolding equilibria are thermody-
namically linked.52 For wt-TTR, the denaturation occurs in a
two-step denaturation process, tetramer to folded monomer
and folded monomer to unfolded monomer.24 The tetramers of
wt-TTR dissociate first into AB and CD dimers (see Figure
2A)11 that then dissociate into four monomers. Thus, any
perturbation of the AB−CD interface might compromise
A25T-TTR tetramer stability.
Pressure-Induced Dissociation of A25T-TTR: Calculat-
ing Thermodynamic Parameters for Folding and
Association. Previously, we have used high hydrostatic
pressure (HHP) to induce dissociation or unfolding of
TTR.17 From HHP isotherms, it is possible to calculate the
change in volume and free energy of a dissociation−unfolding
reaction. Sekijima and co-workers16 have evaluated A25T-TTR
stability using changes in pH to induce TTR dissociation,
Figure 3. Tetramer of A25T-TTR that is less stable when exposed to high hydrostatic pressure than L55P-TTR, as measured by the change in the
center of spectral mass of tryptophan emission. (A) The low temperature facilitates the dissociation and unfolding of A25T-TTR. The experiments
were performed at pH 7.5 with 1 μM A25T-TTR at 37 (●) or 1 °C (▲). (B) The dissociation of A25T-TTR induced by high pressure has some
concentration dependence at 1 °C and pH 7.5. The concentration of A25T-TTR was 1 (▲) or 10 μM (■). (C) At 1 °C and pH 7.5, A25T-TTR
(▼) was less stable than L55P-TTR (◆) when exposed to high pressure. The changes in tryptophan fluorescence emission were used to calculate
the extent of the reaction (α) using eq 2. (D) Plot of ln[α4/(1 − α)] vs pressure for A25T-TTR (▼) or L55P-TTR (◆) extracted from the data
presented in panel C. From these curves, ΔVa and ΔGa were calculated (Table 2) from the slope and y-intercept, respectively. Empty symbols at the
left of panels A−C represent the centers of spectral mass of tryptophan emission after a return to atmospheric pressure. The complete recovery of
this value suggests full reversibility of the dissociation−unfolding processes. Excitation was set at 280 nm and emission collected between 300 and
400 nm.
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partial unfolding, and aggregation; however, these processes all
occur concomitantly, making it very difficult to study each
process in isolation. Urea-induced unfolding has also been
investigated for several variants of TTR, including A25T-
TTR.16,20,25 However, the thermodynamic parameters associ-
ated with its unfolding have not been calculated.
Our first aim was to determine whether A25T-TTR
denaturation under pressure was temperature- and concen-
tration-dependent. Pressure titration assays were performed at
two different temperatures (1 and 37 °C), and structural
perturbations were monitored by analyzing the changes in the
center of the spectral mass of tryptophan (Trp) fluorescence
emission. Each TTR monomer has two Trp residues that can
be used to detect changes in the tertiary structure of the
protein. As seen in Figure 3A, under pressure there was a
displacement of ∼6 nm in the center of mass of Trp
fluorescence emission at these two temperatures, with A25T-
TTR being more sensitive to HHP-induced denaturation at the
lower temperature (1 °C). The p1/2 values (pressure that
furnishes 50% of the maximum structural alterations) at 1 and
37 °C were 600 and 1400 bar, respectively. These data
reinforce the role of hydrophobic interactions in maintaining
the native tetrameric TTR structure.17 The effects of pressure
were completely reversible, as shown by the isolated symbols
on the left of panel A. As shown in Figure 3B, the dissociation
of A25T-TTR at 1 °C was somewhat dependent on
concentration. With a change in protein concentration from 1
to 10 μM, there was an increase in p1/2 from 600 ± 30 to 860 ±
58 bar [n = 3; p < 0.05; Student's t test; Δp1/2 = 260 bar
(Figure 3B)]. However, according to eq 4 (Experimental
Procedures), the expected Δp1/2 is 400 bar. This departure
from the expected displacement on the pressure curve has been
observed for other oligomers57 and has been attributed to
conformational heterogeneity, which increases as the number of
subunits of the oligomer increases.
For the comparison of the stability of A25T-TTR to that of
another unstable TTR variant, we chose L55P-TTR, which is
associated with the most aggressive form of FAP.58 At 1 °C,
A25T-TTR was significantly more sensitive to pressure
denaturation than L55P-TTR (Figure 3C), which had a p1/2
value of 900 bar, 300 bar higher than that of A25T-TTR (Table
2).
From the data presented in panel C and eq 3, it is possible to
calculate the changes in free energy (ΔGa) and volume (ΔVa)
for the association and folding of A25T-TTR and L55P-TTR.
The y-intercept of these curves corresponds to ΔGa, and the
slope corresponds to ΔVa (Table 2).
As shown, A25T-TTR was less thermodynamically stable
than L55P-TTR by 3 kcal/mol. Previous studies investigating
the urea-induced unfolding of these variants determined U1/2
values of 1.9 and 2.3 M for A25T-TTR and L55P-TTR,
respectively,20 suggesting that A25T-TTR is less stable the
L55P-TTR. The thermodynamic stability profile of A25T-TTR
denatured by urea showed that both tetramers and monomers
of this variant are highly destabilized with a complicated
denaturation pathway that includes formation of aggregates.24
The ΔGa was not calculated in these studies.
19,24 Interestingly,
the ΔVa for the dissociation of A25T-TTR was significantly
lower than that observed for L55P-TTR (Table 2). The change
in volume upon association was ∼100 mL/mol higher for
L55P-TTR than for A25T-TTR, suggesting that the tetramers
of L55P-TTR have more void volumes than the A25T-TTR
tetramers. Consequently, the dissociation of this hydrated
mutant should be accompanied by a smaller change in volume
(Figure 3 and Table 2).
Fibrillogenesis of A25T-TTR under Physiological
Conditions. Acidic pH has been frequently used as a way to
trigger TTR amyloidogenesis because it induces the formation
of a monomeric amyloidogenic intermediate of TTR, which is
prone to aggregation.18 However, acidic buffers are poor
models for the conditions in CSF, which is where A25T-TTR
undergoes fibrillogenesis. To mimic the conditions found in
CSF (pH 7.3) more closely, A25T-TTR (3.5 μM) was allowed
to aggregate at pH 7.3 (37 °C), and the appearance of
aggregates over time was followed using size-exclusion
chromatography (SEC). Wild-type TTR and L55P-TTR were
used for comparison. By the second day of incubation, A25T-
TTR (pH 7.3; T2) formed higher-molecular weight species
(eluting at ∼7 mL) than the A25T tetramer, which elutes at 9
mL (Figure 4A). These aggregates underwent increases in
quantity and molecular mass as aggregation progressed [note
the gradual shift in the peak from 7 to ∼6 mL (Figure 4A,
inset)], with a concomitant decrease in the tetramer
population. Even after 20 days under these aggregation-
permitting conditions (T20), some tetramers remained in
solution (∼60%). In contrast, wt-TTR did not aggregate on
this time scale under these conditions (Figure 4Β), while L55P-
TTR underwent minor aggregation in this environment (Figure
4C). The quantification of A25T- and L55P-TTR soluble
oligomer formation as a function of time (pH 7.3) is shown in
Figure 4D.
To further characterize the oligomers formed by aggregation
of A25T-TTR, we took advantage of A11, an oligomer-specific
antibody that does not recognize mature amyloid fibrils.59 As
shown in the inset of Figure 4D, A25T-TTR oligomers were
recognized by A11 on the 11th day of incubation, no wt-TTR
oligomers were detected, and only a small quantity of L55P-
TTR oligomers was detected.
Native PAGE (12%) was also used to follow the aggregation
of A25T-, L55P-, and wt-TTR (Figure 4E), and the tetramer
population was quantified by densitometry (Figure 4F). As
aggregation progresses, the magnitude of the band correspond-
ing to the aggregated species (>270 kDa) increases with L55P-
TTR (lanes 3, 6, 9, and 12) and A25T-TTR (lanes 4, 7, 10, and
13), but this increase was much more pronounced with A25T-
TTR. Again, wt-TTR did not aggregate at this pH (lanes 2, 5, 8,
and 11). Quantification of the disappearance of the tetramer
over time confirmed the stronger tendency of A25T-TTR to
undergo aggregation at neutral pH (Figure 4F). In addition to
soluble oligomers, mature fibrils also formed when A25T-TTR
and L55P-TTR aggregated at neutral pH, as determined by
thio-T, a specific dye for amyloid fibrils. As expected, soluble
A25T-TTR bound very little thio-T (Figure 4G) but, after 20
Table 2. ΔGa and ΔVa Values for the Dissociation of A25T-
TTR and L55P-TTR Tetramers at 1 °C, Calculated Using eq
3
L55P-TTR A25T-TTR
ΔVa (mL/mol) 278 ± 13a 182 ± 39a
ΔGa (kcal/mol) −26.8 ± 0.2a −23.6 ± 0.6a
p1/2 (bar) 900 600
aErrors were calculated by statistical analysis and represent standard
deviations.
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days under aggregating conditions at pH 7.3, formed aggregates
that were thio-T positive (Figure 4G, red bar). L55P-TTR
binds 70% less thio-T than A25T-TTR (Figure 4G, blue bar),
whereas wt-TTR did not produce any species that were able to
bind this dye, even after incubation for 20 days at pH 7.3
(Figure 4G).
Taken together, these data suggest that A25T-TTR under-
goes aggregation at pH 7.3, a pH mimicking that found in CSF,
forming oligomers and amyloid fibrils (see the images of these
fibrils in Figure 5C).
A25T-TTR Fibrillogenesis Takes Place in Human CSF.
Having shown that A25T-TTR is amyloidogenic in buffer at
neutral pH (Figure 4), we decided to investigate whether
A25T-TTR would undergo aggregation in CSF, the milieu in
which this variant aggregates in LA patients. L55P-TTR was
used as a control for this experiment. Aggregation of
recombinant A25T- or L55P-TTR (3.5 μM) in PBS or CSF
was monitored using native PAGE combined with Western
blotting to quantify the disappearance of tetramers (Figure 5,
panels A and B).
Figure 4. Aggregation kinetics of A25T-TTR, L55P-TTR, and wt-TTR at 37 °C and pH 7.3. A25T-TTR (A), wt-TTR (B), and L55P-TTR (C)
(each at 3.5 μM) were incubated in PBS for 20 days at 37 °C under quiescent conditions. During this time, aliquots were withdrawn at the indicated
times [day 0 (black), day 2 (green), day 5 (purple), day 8 (red), day 12 (orange), and day 20 (blue)] and injected into a gel filtration column
(GPC300), and the fluorescence at 330 nm was monitored. Note that in the case of Α25Τ-ΤΤR, the magnitude of the peak corresponding to the
tetramers (elution at 9 mL) decreased over time, while the magnitude of the peak corresponding to aggregates and/or oligomers (elution at 6−7
mL) increased. (D) Quantification of the oligomers formed during the aggregation of A25T-TTR (A) or L55P-TTR (C). The total amount of
oligomers formed during the kinetic assay was quantified by calculating the total area of the peaks eluting before 9 mL. The inset of panel D shows a
dot blot of A25T-TTR, wt-TTR, and L55P-TTR (3.5 μM) after incubation for 11 days in PBS at pH 7.3 and 37 °C using the A11 antibody (which
recognizes prefibrillar oligomers) and an anti-TTR antibody as a loading control. (E) Time course of aggregation of 3.5 μM A25T-TTR (lanes 4, 7,
10, and 13), L55P-TTR (lanes 3, 6, 9, and 12), and wt-TTR (lanes 2, 5, 8, and 11) over 3 days at 37 °C. Aliquots were withdrawn on days 0−3 and
analyzed using 12% native PAGE. Note that over time, the band corresponding to the tetramers (54 kDa) in the A25T-TTR lane decreased in
intensity, with a concomitant increase in the intensity of the bands with molecular masses of >200 kDa. wt-TTR remained tetrameric, whereas L55P-
TTR underwent a discrete aggregation. (F) The quantity of tetramers was estimated by densitometry of the bands at 54 kDa from panel E. (G) The
aggregates of A25T-TTR and L55P-TTR formed in PBS (3.5 μM; 37 °C for 20 days) bind thioflavin T. Soluble A25T-TTR was used as a control.
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Before aggregation (day 0), there are equal amounts of
A25T-TTR (Figure 5Α, lanes 1 and 2) and L55P-TTR (lanes 3
and 4) in PBS and CSF, as measured using a TTR-specific
antibody (54 kDa band). As expected, CSF had a small amount
of endogenous TTR (Figure 5A, lane 5). The samples were
then incubated at 37 °C without agitation, and aliquots were
withdrawn daily and assayed using native PAGE. The gel shown
in the bottom panel of Figure 5A illustrates the profile after
incubation for 15 days under these conditions. The population
of A25T-TTR tetramers (54 kDa band) decreased considerably
over time (Figure 5B); this effect was not observed with L55P-
TTR, whose tetramer population decreased by only ∼15%.
Aggregation of A25T-TTR was equally effective in the two pH-
neutral environments investigated here, which differ in their
compositional complexity.
To verify the nature of the A25T-TTR aggregates in PBS or
CSF, the samples were pelleted and the pellets were analyzed
by electron microscopy (EM), thio-T fluorescence, and Congo
red binding. EM analysis of A25T-TTR aggregates after
aggregation for 15 days in PBS or CSF (panel C or D of
Figure 5, respectively) showed a typical amyloid pattern in both
samples. These aggregates were able to bind thio-T (Figure 5E)
and exhibit Congo red binding (Figure 5F), confirming their
amyloid characteristic. As far as we know, this is the first image
of an aggregate of TTR generated in vitro in an environment
that closely models its physiological setting.
Figure 5. Evaluation of the aggregation of A25T-TTR and L55P-TTR in cerebrospinal fluid (CSF). (A) A25T-TTR (lanes 1 and 2) and L55P-TTR
(lanes 3 and 4) at concentrations of 3.5 μM were allowed to aggregate in PBS (lanes 1 and 3) or CSF (lanes 2 and 4) for 15 days at 37 °C. Samples
were withdrawn each day and analyzed using native PAGE and Western blotting with an anti-TTR antibody. Lane 5 shows the TTR endogenously
expressed in CSF. The top gel in panel A shows a native PAGE/western blotting analysis performed immediately after the addition of 3.5 μM of each
variant into PBS and CSF, showing that the amount of tetramers at time 0 is the same in all conditions. The bottom gel in panel A shows an example
of the band corresponding to the tetramer after incubation for 15 days at 37 °C. Note that there was a marked decrease in the tetramer population,
especially in the case of A25T-TTR. (B) Quantification by densitometry of the band corresponding to the tetramers during the formation of A25T-
TTR and L55P-TTR aggregates. That raw data are for day 15 only. Electron microscopy images of pelleted A25T-TTR fibrils aged for 15 days at 37
°C at PBS (C) or CSF (D). The scale bar is 100 nm. (E) Thioflavin T fluorescence (20 μM) of the fibrils presented in panels C and D (protein
concentration of 45 μg/mL). As controls, soluble A25T-TTR (45 μg/mL) and buffer without protein were used. (F) Fluorescence emission imaging
of Congo red (10 μM) bound to the aggregates of A25T-TTR formed in PBS or CSF. The first panel shows the emission of Congo red in the
presence of soluble protein (negative control). Images are shown at 2000× magnification.
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The Aggregates of A25T-TTR Formed in CSF Bind
Several Proteins. Amyloid deposits formed in vivo are
composed mostly of a single protein, but a variety of other
proteins, such as serum amyloid P, are often associated with the
amyloid fibrils.60 These amyloid fibril-associated proteins
commonly result in enhanced fibril resistance to immune
defense mechanisms or to protease degradation.60 To evaluate
whether A25T-TTR aggregates bound other proteins from
human CSF, recombinant A25T-TTR was added to human
CSF and incubated for 15 days at 37 °C. The samples were
then centrifuged to collect the aggregates, washed twice to
remove any loosely bound proteins, and analyzed by SDS−
PAGE (sample preparation scheme at the top of Figure 6).
When aggregation was performed in PBS (Figure 6A, lane 1),
TTR existed mostly as a monomer after SDS boiling of the
fibrils that are sensitive to SDS, but there were also other visible
bands, one with a molecular mass of approximately 50 kDa
suggesting the presence of SDS-resistant tetramers. Interest-
ingly, when aggregation was performed in CSF (Figure 6A, lane
2), a variety of additional proteins were bound to, and
coprecipitated with, the A25T-TTR amyloid fibrils. It is
important to note that these aggregates are typical amyloid
fibrils as observed by EM, as well as thio-T and Congo red
binding (Figure 5C−F). As a control, a solution of recombinant
wt-TTR (3.5 μM) was incubated in human CSF for 15 days at
37 °C (Figure 6A, lane 3). The absence of proteins in this lane
indicates that neither the endogenous proteins present in CSF
nor wt-TTR demonstrated a tendency to aggregate under these
conditions. Collectively, these experiments suggest that the
aggregates formed in CSF are composed of exogenous A25T-
TTR, which binds several proteins present in this complex
environment. To determine whether A25T-TTR amyloido-
genesis is driven by these protein interactions in the CSF or
whether the associated proteins are brought down as ligands to
the amyloid fibrils, A25T-TTR amyloid fibrils preformed in
PBS for 15 days at 37 °C (Figure 5C) were pelleted and
incubated for an additional 15 days in CSF at 37 °C. The
preformed fibrils of A25T-TTR recruited far fewer CSF
proteins when compared to A25T-TTR fibrils produced in
the CSF (data not shown). This result suggests that proteins
from CSF associate with A25T-TTR both during the
aggregation process and after the formation of mature amyloid
fibrils.
Next, we used a proteomics methodology to identify the
proteins that co-aggregate with A25T-TTR amyloid fibrils. For
this purpose, we submitted two independent batches of A25T-
TTR amyloid fibrils aged for 15 days in CSF to nano LC−MS/
MS proteomics analysis (scheme at the top of Figure 6). To
ensure that the proteins identified were from human CSF and
not a contaminant present in the A25T-TTR recombinant
Figure 6. Aggregates of A25T-TTR in human CSF bind several endogenous proteins. Identification by proteomics analysis. On top: Design of
proteomics experiments to identify by LC−MS/MS CSF proteins copurified with A25T-TTR during amyloid aggregation. (A) SDS−PAGE of 3.5
μM A25T-TTR incubated at 37 °C for 15 days in PBS (lane 1) or CSF (lanes 2). After this period, the samples were washed twice to remove
nonspecifically bound proteins, and the pellets were applied to the gel (A) or subjected to LC−MS/MS (B). As a control, CSF (lane 3) with 3.5 μM
wt-TTR was incubated under the same condition to determine if the endogenous proteins alone or with wt-TTR undergo aggregation. Soluble CSF
(lane 4) was also used as a control. (B) Overlap between the proteins identified in samples 1 and 2. Total numbers of identified proteins are given in
parentheses. Below is the proteomic profile of 19 proteins identified in samples 1 and 2 (for details, see Table 3).
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protein, we applied the same protocol to A25T-TTR fibrils
produced in PBS. As expected, we identified only TTR by LC−
MS/MS in the fibrils formed in PBS. For the A25T-TTR fibrils
aged in CSF, 19 amyloid-associated proteins were common to
both CSF samples (Figure 6B and Table 3). All 19 of the
A25T-TTR amyloid-associated proteins are found naturally in
human CSF samples, as confirmed by our CSF proteomic
analysis (Table 1 of the Supporting Information) or by previous
reports.61
Among the CSF proteins identified, clusterin, apolipoprotein
E, and actin have been previously associated with many other
amyloids, including transthyretin amyloid fibrils.50,62−64 Com-
plement proteins have also been shown to be associated with
amyloid fibrils. We found not only complement proteins (C3,
C4A, C1qB, and C1s) but also immunoglobulins (IGHG1,
JGHA1, and IGHG3) associated with A25T-TTR fibrils,
suggesting activation of the immune system upon TTR amyloid
formation. Fibrinogen has also been found in amyloid plaques
from patients with Alzheimer's disease.65 Besides fibrinogen, we
detected kininogen-1 and antithrombin-III, suggesting a
possible link between A25T-TTR fibrillogenesis and the
blood coagulation cascade in the CSF. A connection between
perturbations of the coagulation and fibrinolytic systems and
the process of amyloidogenesis has been suggested pre-
viously.66 Recruitment of proteins associated with blood
hemostasis to A25T-TTR amyloid fibrils may be useful in
explaining the micro bleeds and subarachnoid hemorrhages
integral to LA pathology.67 The relevance of fibulin-1, EGF-
containing fibulin-like extracellular, monocyte differentiation
antigen CD14, and ceruloplasmin to LA development may be
addressed in the future.
■ CONCLUSIONS
The results of this study quantitatively confirm that A25T-TTR
is highly amyloidogenic and forms amyloid fibrils in CSF. The
protein molecules associated with the A25T-TTR amyloid
fibrils are highly complex and diverse, implicating the
disruption of many cellular and extracellular physiological
pathways, which may play a role in disease development
depending on the extent of perturbation. This complexity is
also present in intracellular protein aggregates, as published
recently by the groups of Vabulas and Hartl.68 In this case, the
loss of function of the recruited proteins was proposed as a
possible explanation for the toxicity of amyloid aggregates, a
hypothesis that should also be considered in LA. The data
described herein prompt new questions. Are the co-aggregated
proteins identified here specific for the aggregation of A25T-
TTR? What is the contribution of these partners to fibril
stability and clearance? We believe that these are some of the
important questions that should be addressed in the future. The
success achieved here in tracking the aggregation of TTR in
CSF opens several new avenues of investigation, such as the
screening of possible inhibitors of fibrillogenesis in a more
relevant environment for LA or FAP.69
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Table 3. Characterization by LC−MS/MS of Proteins Copurified with A25T-TTR Amyloid Fibrilsa
accession code protein gene name biological process
no. of observed
peptidesb
Mascot
scoreb emPAIb,c
AAA85332.1 complement C3 C3 inflammatory response/
complement pathway
23/8 1575/556 0.72/0.26
ΑΑΑ51ϰ55.1 complement C4-A C4A inflammatory response/
complement pathway
15/3 1044/219 0.32/0.06
P02746 complement C1q subcomponent subunit
B
C1QB inflammatory response/
complement pathway
1/3 50/143 0.14/0.51
BAA86864.1 complement C1s subcomponent C1S inflammatory response/
complement pathway
2/1 123/53 0.21/0.14
P01857 Ig γ-1 chain C region IGHG1 Inflammatory response 2/7 98/446 0.20/0.64
B45874 Ig α-1 chain C region IGHA1 inflammatory response 2/2 111/111 0.20/0.20
CAA67886.1 Ig γ-3 chain C region IGHG3 inflammatory response 2/5 104/308 0.20/0.66
CAA29999.1 monocyte differentiation antigen CD14 CD14 inflammatory response 1/1 65/65 0.09/0.09
AAA51765.1 clusterin CLU apoptosis/inflammatory response 1/1 82/81 0.08/0.08
NP_000884.1 kininogen-1 KNG1 blood coagulation/inflammatory
response
3/1 195/59 0.34/0.08
AAA52429.1 fibrinogen β chain FGB blood coagulation 4/6 273/356 0.30/0.48
AAB59531.1 fibrinogen γ chain FGG blood coagulation 1/1 66/66 0.07/0.07
1ATH_A antithrombin-III SERPINC1 blood coagulation 1/1 62/62 0.08/0.08
AAV38664.1 apolipoprotein D APOD lipid transport 2/1 150/81 0.82/0.13
1H7I_A apolipoprotein E APOE lipid transport 4/1 280/75 0.59/0.20
NP_001034438.1 EGF-containing fibulin-like extracellular
matrix protein 1
EFEMP1 peptidyl-tyrosine
phosphorylation
8/4 522/280 0.66/0.38
AAK37822.1 fibulin-1 FBLN1 host−virus interaction 11/2 785/191 0.71/0.12
CAA45026.1 actin, cytoplasmic 1 ACTB adherents junction organization 1/1 97/77 0.09/0.09
BAA08084.1 ceruloplasmin CP oxidation−reduction process 3/1 153/60 0.12/0.04
aSignificance threshold of p < 0.05 (Mascot score of >45). bSample 1/sample 2. cExponentially Modified Protein Abundance Index (emPAI).
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